-
- Posted Wednesday September 28, 2011
TGen Drug Development (TD2) recognized for economic development of Arizona biosciences
TGen's Scottsdale subsidiary helps pharmaceutical firms benefit
patients
SCOTTSDALE, Ariz. - Sept. 28, 2011 - TGen Drug Development (TD2)
won a Fast Lane award from the Arizona BioIndustry Association
(AZBio) for promoting the economic development of Arizona
biosciences.
TD2, a subsidiary of the Translational Genomics Research Institute
(TGen), provides world-class clinical and regulatory expertise to
biopharmaceutical companies using cutting-edge technology to
minimize the risks in cancer drug development. TD2 works to shorten
the development cycles for anti-cancer agents and improve their
success rates.
"TD2 is at the forefront of helping pharmaceutical companies
navigate the regulatory system to get the safest, most effective
compounds as quickly as possible to the patients who need them,"
said Dr. Stephen Gately, President and Chief Scientific Officer of
TD2.
"This award not only recognizes the good work of TD2, but is
reflective of all the advancements of TGen, and of our
collaborators."
Another recipient of a Fast Lane award is Flagship Biosciences,
which provides tissue analysis services. Earlier this year, the
Flagstaff company forged a strategic alliance with TD2 to help
speed new drugs safely into human testing, where they can quickly
benefit cancer patients.
Since 2002, according to Battelle: jobs in Arizona's bioscience
industry grew 32 percent; the number of bioscience and related
firms including research, manufacturing, testing, medical labs, and
healthcare delivery systems grew 28 percent; and research
partnerships with the National Institutes of Heath (NIH) increased
65 percent. Arizona bioscience organizations now generate $21
billion in annual revenues and $765 million in state and local
taxes.
"These are measurable results from a community committed to working
together to build a world-class research base, support
commercialization efforts, and migrate the latest discoveries from
the bench to the bedside in a manner that is both translational and
transformational," said Joan Koerber-Walker, President and CEO of
AZBio. "Organizations like TD2 and their partners ensure that we
keep advancing healthcare at an ever increasing rate."
In announcing the Fast Lane awards, the association noted that
almost every news article about economic recovery points to two key
driving factors, innovation and jobs. "Combining both in a way that
is delivering measurable results is Arizona's bioscience sector.
Thanks to a coordinated plan developed in 2002 and supported by
leaders from Arizona's healthcare industry, corporations,
government and universities, Arizona is moving forward faster in
economic development, job creation and bioscience research."
TD2 officials will join Arizona scientists and biosciences
organizations and businesses at the Arizona BioIndustry
Association's AZBio Expo awards gala Oct. 13 at the Sheraton Wild
Horse Pass in Chandler, Ariz. For more information about AZBio and
the AZBio Awards, please visit www.AZBio.org and
www.AZBioExpo.com.
# # #
About TD2
TGen Drug Development (TD2), a wholly owned subsidiary of the
Translational Genomics Research Institute (TGen), is a 501(c) 3
non-profit organization. TD2 provides innovative services for
oncology focused biopharmaceutical companies using a dedicated team
of professionals with broad experience and understanding in drug
development. TD2 is uniquely positioned to support the need for
improved and accelerated development of new chemical entities
(NCE's) for life-threatening diseases. TD2 uses a unique
combination of experience gained through its contract research
organization business, and an integrated suite of proprietary and
non-proprietary tools, preclinical study execution, regulatory
affairs assistance, clinical trial design and management, and drug
development experts to successfully move therapeutics towards
regulatory approval. TD2 is dedicated to reducing the risks and
uncertainty inherent in the drug development process. For more
information, visit www.td2.org.
